pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › HRMY

HRMY PDUFA Date: WAKIX

FDA decision (PDUFA) target 2026-06-30 · Harmony Biosciences Holdings Inc. · GI symptoms

HRMY run-up into the PDUFA (last ~120 days)

$35.48$26.54
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-06-30
Drug / candidateWAKIX
IndicationGI symptoms
CompanyHarmony Biosciences Holdings Inc.
Market-cap tierSmall
Cohort decision-day move (history)±3% median
ClinicalTrials.gov—

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the HRMY PDUFA date?
The FDA PDUFA target date for HRMY (Harmony Biosciences Holdings Inc.) is 2026-06-30 for WAKIX. Dates are company/FDA-sourced and can slip — verify against primary filings.
What is HRMY's drug WAKIX?
WAKIX is Harmony Biosciences Holdings Inc.'s candidate under FDA review for GI symptoms.
What typically happens to a small-cap stock into a PDUFA date?
Historically, small-cap names had a median decision-day move around ±3% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.